CuralysMD™ combines SMRTActiv™ Technology with colloidal oatmeal to repair the skin barrier and reduce inflammation at the source—delivering lasting relief from atopic dermatitis.
Preclinical studies on the SMRTActiv™ platform demonstrate a robust ability to impact key biological pathways associated with skin inflammation and barrier dysfunction.
CuralysMD™ has been evaluated in two randomized, double-blind, vehicle-controlled clinical studies — one in adults and one in pediatric patients with mild-to-moderate atopic dermatitis (AD).
